WUGEN’s UCART7 Built on Fratricide-Resistant & Allo-Tolerant CART-T Platform Targeting T-Cell Malignancies

WUGEN’s UCART7 Built on Fratricide-Resistant & Allo-Tolerant CART-T Platform Targeting T-Cell Malignancies

WUGEN Inc. was launched in 2018 to develop and commercialize a novel CAR-T therapy platform including “off-the-shelf” fratricide-resistant CAR-T cell therapy for T-cell malignancies. By securing an exclusive license agreement from Washington University in...

Pin It on Pinterest